Circular RNA circ_0010235 sponges miR-338-3p to play oncogenic role in proliferation, migration and invasion of non-small-cell lung cancer cells through modulating KIF2A

References

• Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446–454.
   PubMed Web of Science ®Google Scholar
• Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389(10066):299–311.
   PubMed Web of Science ®Google Scholar
• Ma Y, Zhang X, Wang YZ, et al. Research progress of circular RNAs in lung cancer. Cancer Biol Ther. 2019;20(2):123–129.
   PubMed Web of Science ®Google Scholar
• Li C, Zhang L, Meng G, et al. Circular RNAs: pivotal molecular regulators and novel diagnostic and prognostic biomarkers in non-small cell lung cancer. J Cancer Res Clin Oncol. 2019;145(12):2875–2889.
   PubMed Web of Science ®Google Scholar
• de Fraipont F, Gazzeri S, Cho WC, et al. Circular RNAs and RNA splice variants as biomarkers for prognosis and therapeutic response in the liquid biopsies of lung cancer patients. Front Genet. 2019;10:390.
   PubMed Web of Science ®Google Scholar
• Jiang MM, Mai ZT, Wan SZ, et al. Microarray profiles reveal that circular RNA hsa_circ_0007385 functions as an oncogene in non-small cell lung cancer tumorigenesis. J Cancer Res Clin Oncol. 2018;144(4):667–674.
   PubMed Web of Science ®Google Scholar
• Zhang S, Zeng X, Ding T, et al. Microarray profile of circular RNAs identifies hsa_circ_0014130 as a new circular RNA biomarker in non-small cell lung cancer. Sci Rep. 2018;8(1):2878.
   PubMed Web of Science ®Google Scholar
• Ma D, Qin Y, Huang C, et al. Circular RNA ABCB10 promotes non-small cell lung cancer progression by increasing E2F5 expression through sponging miR-584-5p. Cell Cycle. 2020;19(13):1611–1620.
   PubMed Web of Science ®Google Scholar
• Ahn YH, Ko YH. Diagnostic and therapeutic implications of microRNAs in non-small cell lung cancer. Int J Mol Sci. 2020;21(22):8782.
   PubMed Web of Science ®Google Scholar
• Leonetti A, Assaraf YG, Veltsista PD, et al. MicroRNAs as a drug resistance mechanism to targeted therapies in EGFR-mutated NSCLC: current implications and future directions. Drug Resist Updates. 2019;42:1–11.
   PubMed Web of Science ®Google Scholar
• Li Y, Chen P, Zu L, et al. MicroRNA-338-3p suppresses metastasis of lung cancer cells by targeting the EMT regulator Sox4. Am J Cancer Res. 2016;6(2):127–140.
   PubMed Web of Science ®Google Scholar
• Zhang P, Shao G, Lin X, et al. MiR-338-3p inhibits the growth and invasion of non-small cell lung cancer cells by targeting IRS2. Am J Cancer Res. 2017;7(1):53–63.
   PubMed Web of Science ®Google Scholar
• Zhang G, Zheng H, Zhang G, et al. MicroRNA-338-3p suppresses cell proliferation and induces apoptosis of non-small-cell lung cancer by targeting sphingosine kinase 2. Cancer Cell Int. 2017;17:46.
   PubMed Web of Science ®Google Scholar
• Tsakonas G, Ekman S. Oncogene-addicted non-small cell lung cancer and immunotherapy. J Thorac Dis. 2018;10(Suppl. 13):S1547–S1555.
   PubMed Web of Science ®Google Scholar
• Schulze AB, Evers G, Kerkhoff A, et al. Future options of molecular-targeted therapy in small cell lung cancer. Cancers (Basel). 2019;11(5):690.
   PubMed Web of Science ®Google Scholar
• Zaganjor E, Weil LM, Gonzales JX, et al. Ras transformation uncouples the kinesin-coordinated cellular nutrient response. Proc Natl Acad Sci U S A. 2014;111(29):10568–10573.
   PubMed Web of Science ®Google Scholar
• Zaganjor E, Osborne JK, Weil LM, et al. Ras regulates kinesin 13 family members to control cell migration pathways in transformed human bronchial epithelial cells. Oncogene. 2014;33(47):5457–5466.
   PubMed Web of Science ®Google Scholar
• Uchida A, Seki N, Mizuno K, et al. Regulation of KIF2A by antitumor miR-451a inhibits cancer cell aggressiveness features in lung squamous cell carcinoma. Cancers (Basel). 2019;11(2):258.
   PubMed Web of Science ®Google Scholar
• Xie T, Li X, Ye F, et al. High KIF2A expression promotes proliferation, migration and predicts poor prognosis in lung adenocarcinoma. Biochem Biophys Res Commun. 2018;497(1):65–72.
   PubMed Web of Science ®Google Scholar
• Pei X, Chen SW, Long X, et al. circMET promotes NSCLC cell proliferation, metastasis, and immune evasion by regulating the miR-145-5p/CXCL3 axis. Aging (Albany NY). 2020;12(13):13038–13058.
   PubMedGoogle Scholar
• Wang L, Tong X, Zhou Z, et al. Circular RNA hsa_circ_0008305 (circPTK2) inhibits TGF-beta-induced epithelial–mesenchymal transition and metastasis by controlling TIF1gamma in non-small cell lung cancer. Mol Cancer. 2018;17(1):140.
   PubMed Web of Science ®Google Scholar
• Zheng D, Haddadin S, Wang Y, et al. Plasma microRNAs as novel biomarkers for early detection of lung cancer. Int J Clin Exp Pathol. 2011;4(6):575–586.
   PubMed Web of Science ®Google Scholar
• Yang T, Li H, Chen T, et al. LncRNA MALAT1 depressed chemo-sensitivity of NSCLC cells through directly functioning on miR-197-3p/p120 catenin axis. Mol Cells. 2019;42(3):270–283.
   PubMed Web of Science ®Google Scholar
• Weng L, Qiu K, Gao W, et al. LncRNA PCGEM1 accelerates non-small cell lung cancer progression via sponging miR-433-3p to upregulate WTAP. BMC Pulm Med. 2020;20(1):213.
   PubMed Web of Science ®Google Scholar
• Li S, Niu X, Li H, et al. Circ_0000003 promotes the proliferation and metastasis of non-small cell lung cancer cells via miR-338-3p/insulin receptor substrate 2. Cell Cycle. 2019;18(24):3525–3539.
   PubMed Web of Science ®Google Scholar
• Chen Q, Guo SM, Huang HQ, et al. Long noncoding RNA SBF2-AS1 contributes to the growth and metastatic phenotypes of NSCLC via regulating miR-338-3p/ADAM17 axis. Aging (Albany NY). 2020;12(18):17902–17920.
   PubMedGoogle Scholar
• Yang Z, Lin X, Zhang P, et al. Long non-coding RNA LINC00525 promotes the non-small cell lung cancer progression by targeting miR-338-3p/IRS2 axis. Biomed Pharmacother. 2020;124:109858.
   PubMed Web of Science ®Google Scholar
• Welburn JP, Cheeseman IM. The microtubule-binding protein Cep170 promotes the targeting of the kinesin-13 depolymerase Kif2b to the mitotic spindle. Mol Biol Cell. 2012;23(24):4786–4795.
   PubMed Web of Science ®Google Scholar
• Zhang X, Wang Y, Liu X, et al. KIF2A promotes the progression via AKT signaling pathway and is upregulated by transcription factor ETV4 in human gastric cancer. Biomed Pharmacother. 2020;125:109840.
   PubMed Web of Science ®Google Scholar
• Wang J, Ma S, Ma R, et al. KIF2A silencing inhibits the proliferation and migration of breast cancer cells and correlates with unfavorable prognosis in breast cancer. BMC Cancer. 2014;14(1):461.
   PubMed Web of Science ®Google Scholar
• Wang CQ, Qu X, Zhang XY, et al. Overexpression of Kif2a promotes the progression and metastasis of squamous cell carcinoma of the oral tongue. Oral Oncol. 2010;46(1):65–69.
   PubMed Web of Science ®Google Scholar
• Wang G, Wang Z, Yu H. Kinesin family member 2A high expression correlates with advanced tumor stages and worse prognosis in non-small cell lung cancer patients. J Clin Lab Anal. 2020;34(4):e23135.
   PubMed Web of Science ®Google Scholar
• Gan H, Lin L, Hu N, et al. KIF2C exerts an oncogenic role in nonsmall cell lung cancer and is negatively regulated by miR-325-3p. Cell Biochem Funct. 2019;37(6):424–431.
   PubMed Web of Science ®Google Scholar
• Bai Y, Xiong L, Zhu M, et al. Co-expression network analysis identified KIF2C in association with progression and prognosis in lung adenocarcinoma. Cancer Biomark. 2019;24(3):371–382.
   PubMed Web of Science ®Google Scholar